-
COMFORT IS THE NEW LUXURY: MARRIOTT INTERNATIONAL UNVEILS ASIA PACIFIC'S CULINARY FUTURE
Marriott International's Future of Food 2026 reveals how a shift towards comfort-driven luxury and experiences rooted in local culinary traditions are redefining a new era of indulgence SINGAPORE, Oct. 14, 2025 -- Marriott International has unveiled its latest report, The Future of Food 2026, which explores how dining habits and preferences are changing across the Asia Pacific region. The comprehensive study spotlights major trends reshaping the culinary landscape, including a shift away from traditional fine dining toward casual luxury, comfort-driven menus, immersive dining e
- 김장윤(JASON KIM) 기자
- 2025-10-14 16:00
-
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise. Q3 2025 Highlights Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year. FY 2025 revenue guidance increased to $800 million to $820 million[1]. Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services
- 김갑성 기자
- 2025-10-14 14:59
-
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
TAIPEI, Oct. 14, 2025 -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, which is held in Berlin, Germany, from Oct 17 to 21, 2025. Abstract: 2242Title: Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapySession Date/Tim
- 김갑성 기자
- 2025-10-14 14:26
-
밴티지, 파이낸스 매그네이츠 어워드 2025에서 7개 부문 후보 선정
포트빌라, 바누아투 2025년 10월 1일 -- 다중자산 브로커 밴티지(Vantage)가 글로벌 시장에서 이룬 혁신과 우수성을 인정받아 다가오는 파이낸스 매그네이츠 어워드 2025(Finance Magnates Awards 2025)에서 7개 부문 후보에 올랐다. 올해 파이낸스 매그네이츠 어워드 2025에서 밴티지는 다음 영국 부문 후보로 선정됐다. 2025 영국 최고 스프레드 브로커(Best Spreads Broker 2025, UK) 2025 영국 최고 제휴 프로그램 브로커(Best Affiliate Program Broker 2025, UK) 2025 영국 최고 신뢰도 브로커(Most Trusted Broker 2025, UK) 2025 영국 종합 최고 브로커(Best Overall Broker 2025, UK) 또한 베트남 부문에서도 후보에 올랐다. 2025 베트남 최고 신뢰도 브로커(Most Trusted Broker 2025, Vietnam) 2025 베트남 최고 성장 브로커(Fastest Growing Broker 2025, Vietnam
- 황정호 기자
- 2025-10-14 14:19
-
Ericsson reports third quarter results 2025
STOCKHOLM, Oct. 14, 2025 -- Strategic highlights – operational excellence and enhanced financial flexibility Strong commercial momentum with significant customer agreements including in India, Japan and the UK. Operational excellence and cost efficiency actions driving gross margins to strong sustainable levels. 5G Open RAN-ready portfolio breadth and technology leadership position reaffirmed by Gartner and Omdia. Financial highlights – further profitability growth Organic sales declined by -2%, with growth in three out of four market areas. R
- 황정호 기자
- 2025-10-14 14:16
-
밴티지, '2025 스마트 비전 서밋 바레인' 메인 스폰서로 참여… '가장 신뢰받는 브로커 상' 수상
포트빌라, 바투아누 2025년 10월 10일 -- 선도적인 다중자산 브로커인 밴티지(Vantage)가 '스마트 비전 서밋 바레인 2025(Smart Vision Summit Bahrain 2025)'에 메인 스폰서로 참여하며, 주요 업계 행사를 지원하겠다는 의지를 다시 한번 강조했다. 글로벌 브로커, 금융 전문가 및 트레이더들이 한자리에 모인 이번 서밋은 지식 교류, 네트워킹, 온라인 거래 분야의 최신 혁신 기술을 선보이는 플랫폼 역할을 수행했다. 밴티지는 메인 스폰서로서 투명성, 기술, 고객 중심 서비스를 주제로 한 논의에 핵심적인 역할을 담당했다. 또한 밴티지는 이번 행사에서 '가장 신뢰받는 브로커 상(Most Trusted Broker Award)'을 수상하며, 자사의 신뢰성, 투명성, 고객 서비스에 대한 헌신을 다시금 입증했다. 이번 수상을 통해 밴티지는 혁신적인 거래 플랫폼, 안정적인 서비스, 다양한 시장의 트레이더를 위한 맞춤형 지원을 다시 한번 입증했다. 마크 데스팔리에르(Marc Despallieres) 밴티지마켓 최고경영자(CEO)는 "가장 신뢰받는 브
- 황정호 기자
- 2025-10-14 14:10
-
Republic Power Group Limited Announces Pricing of Initial Public Offering
SINGAPORE, Oct. 14, 2025 -- Republic Power Group Limited (the "Company"), a provider of customized enterprise resource planning software solutions, consulting and technical support services, and peripheral hardware, announced the pricing of its initial public offering (the "Offering") of 2,120,000 Class A ordinary shares, 1,250,000 of which are being offered by the Company and 870,000 by selling shareholders at a price to the public of US$4.00 per Class A ordinary share. The Class A ordinary shares have been approved for listing on the Nasdaq Capital Market and are expecte
- 황정호 기자
- 2025-10-14 13:48
-
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. Telitacicept met the primary endpoint and all key secondary endpoints. Patients in Telitacicept groups showed significant improvement in disease activity compared to the placebo group. Approximately 71.8% of patients receiving Telitacicept 160mg achieved an ESSDAI reduction of ≥3 points at 24 w
- 김갑성 기자
- 2025-10-14 13:44
-
HKEX to Introduce Hang Seng Biotech Index Futures
[ 메디채널 황정호 기자 ] Hang Seng Biotech Index Futures to launch on 28 November 2025 New futures contracts offer risk management tools for one of the fastest growing sectors in Hong Kong capital markets SFC Transaction Levy Exemption will be applied for the first six months from launch HONG KONG, Oct. 14, 2025 -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to announce today (Tuesday) plans to launch [ 메디채널 황정호 기자 ] Hang Seng Biotech Index Futures, the latest enhancement to its growing derivatives product ecosystem. The new futures contract, which commences trad
- 황정호 기자
- 2025-10-14 12:43
-
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
SHANGHAI, Oct. 14, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. This marks an important clinical achievement following EVM14's Investigational New Drug (IND) approvals by both the U.S. Food and Drug Adminis
- 김갑성 기자
- 2025-10-14 12:13
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-11-02_SUN
- Torch Relay for the 15th National Games Kicks Off, with Feng Xingya, Chairman and President of GAC Group, Serving as Torchbearer 18:39
- Shining a Light on Kids' Well-Being: ANESSA Sunshine Project Expands to Singapore with JFA | ANESSA Kids Event 12:12
- Novo Tellus、Grand Venture Technologyとの変革的成長パートナーシップを完了 04:28
- Xinhua Silk Road: 중국 기업인들, 문화유산 계승과 혁신 모색 위한 회담 개최 03:36
- 로토부스트, 세계 최대 철강사 바오우와 협력해 천연가스 분해 기반 녹색 철강 산업화 추진 02:32
- iGarden Opens Pre-Sale for Swim Jet P Series -- The Perfect Swim Jet for Home Pool Fun 01:00
2025-11-01_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 11월 02일 20시 20분